Jazz Pharmaceuticals

Jazz Pharmaceuticals

Yahoo Finance • 5 days ago

3 Biotech Stocks With Upside Of Up To 80%

Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech... Full story

Yahoo Finance • 20 days ago

Ziihera’s FDA Win and Leadership Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals recently received US FDA approval for its cancer drug Ziihera and was informed that Executive Vice President and Chief Commercial Officer Samantha Pearce intends to retire by June 30, 2027, or upon the appointment of h... Full story

Yahoo Finance • 22 days ago

3 of Wall Street’s Favorite Stocks That Fall Short

3 of Wall Street's Favorite Stocks That Fall Short Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it's worth remembering that analysts rarely issue... Full story

Yahoo Finance • 22 days ago

Claritas Rx Appoints Biopharma Commercial Leader Jonathan Witt to Board of Directors

Former Genentech Senior Vice President Brings More Than 25 Years of Biopharma Experience to Guide Continued Growth and Patient Impact SOUTH SAN FRANCISCO, Calif., October 13, 2026--(BUSINESS WIRE)--Claritas Rx, the patient journey experts... Full story

Yahoo Finance • 28 days ago

Pheochromocytoma and Paraganglioma (PCPG) Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted and Radioligand Therapies

Company Logo Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective. Dublin, Oct. 08, 2026 (GLOBE NEWSWIR... Full story

Yahoo Finance • last month

Target upgraded, Moderna downgraded: Wall Street's top analyst calls

Target upgraded, Moderna downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • last month

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development

Iambic Therapeutics, Inc., an AI drug discovery company backed by Nvidia Corp.(NASDAQ:NVDA) and the Qatar Investment Authority, filed for an initial public offering, according to an S-1 filing with the SEC on Monday. Plans to List on Nasd... Full story

Yahoo Finance • 2 months ago

3 Cash-Producing Stocks We’re Skeptical Of

3 Cash-Producing Stocks We're Skeptical Of While strong cash flow is a key indicator of stability, it doesn't always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak com... Full story

Yahoo Finance • 2 months ago

2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead

2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead Jazz Pharmaceuticals's 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was partly thanks to its solid qua... Full story

Yahoo Finance • 2 months ago

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Amgen AMGN announced positive results from a phase III study that evaluated its lung cancer therapy Imdelltra (tarlatamab) in combination with AstraZeneca's AZN blockbuster immunotherapy Imfinzi (durvalumab) for certain patients with exten... Full story

Yahoo Finance • 2 months ago

Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere

Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose b... Full story

Yahoo Finance • 2 months ago

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation. The randomized, double-blind, placebo-controlled phase III SUMMIT study is desi... Full story

Yahoo Finance • 2 months ago

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first... Full story

Yahoo Finance • 2 months ago

Jazz Pharmaceuticals prices upsized $1.1B private debt offering

* Jazz Pharmaceuticals (JAZZ [https://seekingalpha.com/symbol/JAZZ]) announced [https://seekingalpha.com/pr/20631578-jazz-pharmaceuticals-announces-pricing-of-upsized-private-offering-of-1_1-billion-of-1_875]the pricing of $1.1B aggregat... Full story

Yahoo Finance • 2 months ago

Dow Jones Futures Await Inflation Data, Nvidia Earnings; Robinhood In Buy Area

The stock market rose Tuesday amid lower oil prices and yields, but cautiously heading into Fed inflation data and Nvidia earnings. Continue Reading... Full story

Yahoo Finance • 2 months ago

Jazz Sparks On Its New Plan To Take On Roche; Hint: It's In Cancer

Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer. Continue Reading... Full story

Yahoo Finance • 2 months ago

Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab

Medical research ©rawpixel Zymeworks (NASDAQ:ZYME) shares climbed nearly 4.0% in pre-market trading as investors positioned themselves ahead of an important U.S. regulatory decision on zanidatamab, expected the following day. The FDA's P... Full story

Yahoo Finance • 3 months ago

Zymeworks gains following addition to Citi catalyst watch

[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. * The bank sees shares rising d... Full story

Yahoo Finance • 3 months ago

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) complete... Full story

Yahoo Finance • 3 months ago

Jazz forecasts $4.60B-$4.75B 2026 revenue as it prepares for Aug. 25 zanidatamab PDUFA

Earnings Call Insights: Jazz Pharmaceuticals (JAZZ) Q2 2026 MANAGEMENT VIEW * Renée Galá (President, CEO & Director) framed the quarter around revenue growth, a guidance raise, and an oncology launch catalyst: "We delivered another out... Full story